|
Market Closed -
Nasdaq Stockholm
20:00:00 23/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.928 SEK | -2.72% |
|
-4.55% | -2.13% |
| 10-20 | Irlab research behind linepemat published in journal | FW |
| 10-20 | IRLAB Therapeutics AB Announces Publication Of Preclinical Research Underpinning Linepemat In Peer-Reviewed Journal | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 28.88M | - | - | - | ||
| 1,135B | |||||
| 635B | |||||
| 505B | |||||
| 378B | |||||
| 358B |
Select your edition
All financial news and data tailored to specific country editions
